Aclipse has successfully conducted the US FDA pre-IND meeting for M102

Aclipse Therapeutics Selected to Present M102 ALS Clinical Development Program at Prestigious ALS and Motor Neurone Disease Symposia

KING OF PRUSSIA, Penn.–(BUSINESS WIRE)–Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that its M102 drug development program has

November 10, 2024

Aclipse Therapeutics Expands Drug Development Pipeline

Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to

September 14, 2023

Aclipse Therapeutics Announces Publication in Nature Reviews Drug Discovery of an Amyotrophic Lateral Sclerosis Review including M102, a First Targeted Therapy for Sporadic ALS

Radnor, PA, USA – January 2, 2023 – Aclipse Therapeutics, and its subsidiary Aclipse One, Inc (“Aclipse” or “the Company”),

January 2, 2023

Aclipse Therapeutics Announces Issuance of Composition-of-Matter Patent for M102, a First Targeted Therapy for Sporadic ALS

Radnor, PA, USA – November 10, 2022 – Aclipse Therapeutics, and its subsidiary Aclipse One, Inc (“Aclipse” or “the Company”),

November 10, 2022

February 16, 2020

Aclipse Therapeutics has successfully conducted the US FDA pre-IND meeting for M102. The FDA has reviewed the M102 preclinical data package and confirmed the necessary preclinical studies for M102 to initiate its first-in-human studies. The agency has also provided valuable guidance to support the clinical development of M102.

Learn more